Dual therapeutic benefits of selective-histone deacetylase 3 inhibition in Huntington's disease mice
(2016) X Symposium of Experimental Neurobiology, Societat Catalana de Biologia — Location: Barcelona, Spain
Files
No attached file found for this publication.
Details
- Authors
- et. al.
- Abstract
- In this project, we demonstrated that the pharmacological inhibition oh HDAC3 with RGFP966 can simultaneously prevent cognitive decline and suppress striatal CAG repeat expansions in a mouse model of Huntington's disease.
- Affiliations
Universitat de Barcelona
Citations
Suelves Caballol, N., Kirkham-Mccarthy L, Lahue RS, Ginés S, & et al. (2016). Dual therapeutic benefits of selective-histone deacetylase 3 inhibition in Huntington’s disease mice. X Symposium of Experimental Neurobiology, Societat Catalana de Biologia, Barcelona, Spain. https://hdl.handle.net/2078.5/238437